Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone.
Fifty-one out-patients presenting with generalised anxiety disorder were included in a double-blind trial, and treated with either buspirone (a new non-benzodiazepine antianxiety drug) or diazepam over 6 or 12 weeks, after which they were abruptly withdrawn and continued on placebo to 14 weeks. Ratings of anxiety and other symptoms were administered fortnightly and additional withdrawal symptoms noted. Forty patients completed the study; 8 of the 11 drop-outs were taking buspirone. Both drugs reduced anxiety, diazepam more rapidly, but with greater withdrawal symptoms, particularly after 6 weeks. Regular treatment with diazepam for 6 weeks leads to a significant risk of pharmacological dependence that is not present with buspirone.
Murphy
S M
SM
Mapperley Hospital, Nottingham, London.
Owen
R
R
Tyrer
P
P
D000293:Adolescent; D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy; D002065:Buspirone / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D003975:Diazepam; D002065:Buspirone